

**For Immediate Release**TSX Exchange Symbol: **RVX****Resverlogix Corp. ReVas™ Licensing Update**

CALGARY, AB, February 23, 2006 – Resverlogix Corp. (“Resverlogix”) (TSX: RVX), on behalf of its subsidiary RVX Therapeutics Inc (“RVX”), has received word that the final wording of a licensing document has been completed. As this subject will be covered in a Vcall conference call today, Resverlogix wishes to avoid selective disclosure and inform the overall market of this updated development.

ReVas™ is an emerging and important research program within RVX that specifically develops unique novel compounds dedicated to improve the outcomes for patients undergoing acute coronary intervention. Restenosis and sudden vascular occlusion is one of the most important complications seen in patients who undergo invasive cardiovascular surgery. It remains an important health issue for health systems globally in the developed world.

**About Resverlogix Corp.**

Resverlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, Resverlogix's lead technology NexVas™, applies advanced medical research to develop therapies that increase high density lipoprotein (HDL), the "good cholesterol," to treat cardiovascular diseases (CVD). The Company's second CVD research program ReVas™ is dedicated to developing novel compounds for acute based drug therapy via a medical device. The company's TGF-Beta Shield™ program utilizes a novel approach to target cancers and fibrotic diseases. Resverlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the TSX Exchange under the symbol RVX. For further information, please visit our web site at: [www.resverlogix.com](http://www.resverlogix.com).

**For further information please contact:****Donald J. McCaffrey**

President/CEO  
Resverlogix Corp.  
Phone: 403-254-9252 ext. 223  
Fax: 403-256-8495  
Email: [don@resverlogix.com](mailto:don@resverlogix.com)

**Kenneth Lebioda**

Vice President Business Development  
Resverlogix Corp.  
Phone: 403-254-9252 ext. 227  
Fax: 403-256-8495  
Email: [ken@resverlogix.com](mailto:ken@resverlogix.com)

Website: [www.resverlogix.com](http://www.resverlogix.com)